Clinical Trial: NCT05679895
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | OneChain Immunotherapeutics |
| Information Provided By: | OneChain Immunotherapeutics |
| Last Update Posted: | 2026-03-11 |
Study Overview
Brief Summary
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)
Official Title
Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed/Refractory (R/R) T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL
Conditions
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma
Intervention / Treatment
- Biological: CD1a-CAR T
Other Study ID Numbers
- OC-01-21001
Start Date (Actual)
2023-01-31
Primary Completion Date (Estimated)
2027-12
Study Completion Date (Estimated)
2027-12
Enrollment (Estimated)
20
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | OneChain Immunotherapeutics |
| Information Provided By: | OneChain Immunotherapeutics |
| Last Update Posted: | 2026-03-11 |
Study Overview
Brief Summary
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)
Official Title
Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed/Refractory (R/R) T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL
Conditions
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma
Intervention / Treatment
- Biological: CD1a-CAR T
Other Study ID Numbers
- OC-01-21001
Start Date (Actual)
2023-01-31
Primary Completion Date (Estimated)
2027-12
Study Completion Date (Estimated)
2027-12
Enrollment (Estimated)
20
Study Type
Interventional
Phase
Phase 1